Chimerix, Inc. (NASDAQ:CMRX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Chimerix, Inc. (NASDAQ:CMRXGet Rating) have earned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have covered the stock in the last year is $8.50.

A number of research firms recently issued reports on CMRX. StockNews.com raised shares of Chimerix from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. Capital One Financial assumed coverage on shares of Chimerix in a research report on Wednesday, September 7th. They set an “overweight” rating and a $7.00 price objective on the stock.

Chimerix Price Performance

CMRX opened at $2.21 on Monday. The firm has a market cap of $194.58 million, a P/E ratio of 1.26 and a beta of 1.08. Chimerix has a 1-year low of $1.27 and a 1-year high of $7.42. The company has a 50 day simple moving average of $1.93 and a two-hundred day simple moving average of $2.15.

Insider Activity at Chimerix

In related news, Director Fred A. Middleton purchased 20,000 shares of Chimerix stock in a transaction dated Thursday, September 29th. The shares were acquired at an average price of $1.86 per share, for a total transaction of $37,200.00. Following the acquisition, the director now directly owns 40,000 shares in the company, valued at $74,400. The purchase was disclosed in a filing with the SEC, which is available through this link. 8.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Chimerix

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp grew its position in shares of Chimerix by 14.2% during the first quarter. State Street Corp now owns 4,561,868 shares of the biopharmaceutical company’s stock worth $20,893,000 after buying an additional 568,498 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Chimerix by 16.1% during the third quarter. Vanguard Group Inc. now owns 4,490,078 shares of the biopharmaceutical company’s stock worth $8,666,000 after purchasing an additional 623,268 shares during the last quarter. Monaco Asset Management SAM grew its holdings in Chimerix by 43.0% during the third quarter. Monaco Asset Management SAM now owns 2,115,936 shares of the biopharmaceutical company’s stock worth $4,084,000 after acquiring an additional 636,753 shares during the period. Dimensional Fund Advisors LP grew its holdings in Chimerix by 11.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,951,521 shares of the biopharmaceutical company’s stock valued at $8,938,000 after purchasing an additional 206,990 shares during the last quarter. Finally, Penn Capital Management Company LLC acquired a new stake in Chimerix in the second quarter valued at $1,764,000. 63.43% of the stock is owned by institutional investors and hedge funds.

About Chimerix

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Read More

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.